TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), Canada’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide is proud to award $50,000 to an exciting research project led by Dr Ian Lorimer and his team at Ottawa Hospital Research Institute (OHRI). The project titled “Improving glioblastoma immunotherapy by selectively blocking macrophage activity” explores a new way of possibly treating glioblastoma (GBM) and might soon pave

The new partnership brings together unified health data and clinical trial matching technology to reduce patient burden, improve enrollment efficiency, and help connect eligible patients to relevant clinical trial opportunities earlier in their care journey BALTIMORE, Md. and AMSTERDAM, May 26, 2026 /PRNewswire/ -- b.well Connected Health ("b.well"), the healthcare technology company unifying fragmented health data into AI-ready longitudinal records, and myTomorrows, a globally leading health te

Grant marks Alveo's entry into vaccine manufacturing market, extending its molecular detection platform beyond infectious disease diagnostics. ALAMEDA, Calif., May 26, 2026 /PRNewswire/ -- Alveo Technologies, Inc. (Alveo), a leader in portable molecular sensing solutions, today announced it has been awarded a grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to explore how its platform, already in use around the globe for pathogen detection, can be used in vaccine manufactur

BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at two upcoming conferences. Hunter Smith will participate in a fireside chat at the Jefferies Global H

VANCOUVER, BC and LAS VEGAS, May 26, 2026 /PRNewswire/ - Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a rapidly growing digital health platform and provider of compliant healthcare infrastructure across the United States, today announced that the Company will release its first quarter 2026 financial results after market close on Monday, June 1, 2026. Management will host an investor webcast and conference call on Tuesday, June 2, 2026 at 6:0

Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitorSixth consecutive positive DSMB recommendation to proceed highlights the favorable safety and tolerability of BriaCell’s novel immunotherapy approach Phase 3 study is being conducted under FDA Fast Track Designation, reflecting the significant unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia,

LONDON, May 26, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS"). In the pilot dataset, ViraxImmune™ demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positiv

Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced plans to expand its ongoing Phase 1b clinical trial evaluating lead asset paxalisib in combination with standard-of-care therapies in pa

Thermostability, immunogenicity and efficacy data against related viruses may provide rapid starting point for vaccine development PRINCETON, N.J., May 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an Orthoebolavirus, will require new vaccine form

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world’s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue micros